«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2014年第4期

页码:

429-432,436

栏目:

临床研究

出版日期:

2014-04-25

文章信息/Info

Title:

Efficacy of amlodipine-valsartan combination in hypertensive patients and its effects on pulse wave velocity

作者:

玉晓露; 赵连友; 张志敏; 邹 青; 卢 凡; 卫聪颖; 丁 璐

(第四军医大学唐都医院心内科，陕西 西安 710038)

Author(s):

YU Xiao-lu;  ZHAO Lian-you;  ZHANG Zhi-min;  ZOU Qing;  LU Fan;  WEI Cong-ying;  DING Lu

(Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710038, China)

关键词:

高血压; 原发性; 脉搏波传导速度;  氨氯地平;  缬沙坦; 心率

Keywords:

essential hypertension;  pulse wave velocity;  amlodipine;  valsartan;  hypertension

分类号:

R544.1

DOI:

-

文献标识码:

A

摘要:

目的:观察氨氯地平联合缬沙坦治疗原发性高血压（essential hypertension,EH）的效果及其对脉搏波传导速度(baPWV)的影响。方法： 将EH患者100例随机分为氨氯地平+缬沙坦组(氨+缬组)和氨氯地平组（氨组），每组各50例。治疗24周后，测定各组血压、心率和baPWV的变化。结果： ①治疗24周后，氨+缬组患者收缩压、舒张压、baPWV均显著低于氨组 ［收缩压:(114±9) mmHg vs.(131±14) mmHg；舒张压:(72±7) mmHg vs.（84±8） mmHg；baPWV:(1457±198) cm/s vs.（1544±222） cm/s，均P<0.05］。②氨+缬组患者治疗后心率与治疗前相比显著降低［(74±12)次/min vs.(68±11)次/min，P<0.05］，而氨组治疗前后心率变化无统计学差异［(73±10)次/min vs.(72±9)次/min］。③氨+缬组和氨组降压治疗的总有效率分别为86%和64%，两者差异有统计学意义（P<0.05）。④氨+缬组随访期间4例患者出现头痛，2例患者出现干咳，氨组有13例出现脚踝水肿，且症状均随治疗自动消失，其余患者均未出现严重不良反应。结论： 氨氯地平联合缬沙坦与氨氯地平单药相比治疗EH的效果更优，安全性更好，并且能降低baPWV，具有逆转动脉硬化的作用。

Abstract:

AIM:To observe the efficacy of amlodipine-valsartan combination in hypertensive patients and its effects on brachial-ankle pulse wave velocity (baPWV). METHODS: One hundred hypertensive patients were randomly divided into amlodipine-valsartan group (n=50) and amlodipine group (n=50). Blood pressure, heart rate and pulse wave velocity were measured for each group before and after 24-week treatment. RESULTS: After the 24-week treatment, SBP, DBP, and baPWV of the hypertensive patients in amlodipine-valsartan combination group were significantly lower than that of amlodipine group ［SBP: (114±9) mmHg vs.(131±14) mmHg; DBP: (72±7) mmHg vs.(84±8) mmHg; baPWV: (1457±198) cm/s vs.(1544±222) cm/sec, all P<0.05). In the amlodipine-valsartan combination group, heart rate of the hypertensive patients were significantly lower ［(74±12)/min vs.(68±11)/min, P<0.05］ after treatment, whereas in the amlodipine group no significant difference ［(73±10)/min vs.(72±9)/min］ was observed. The total efficacy rate of amlodipine-valsartan combination group was higher than that of the amlodipine group (86% vs. 64%, P<0.05). Four hypertensive patients reported headache and two patients in the amlodipine-valsartan combination group had cough. Thirteen hypertensive patients had peripheral edema in the amlodipine group. All symptoms gradually disappeared with the ongoing treatment. No severe adverse side effects occurred during the 24-week treatment. CONCLUSION: Initial combination therapy for hypertension with amlodipine-valsartan is superior to amlodipine monotherapy in efficacy, safety and reversing arteriosclerosis.

参考文献/References

[1]Vlachopoulos C,Aznaouridis K,Stefanadis C.Prediction of cardiovascular events and all-cause mortality with arterial stiffness:a systematic review and meta-analysis[J].J Am Coll Cardiol,2010, 55(13):1318-1327.
[2]中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616.
[3]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:77.
[4]胡大一,刘力生,余金明,等.中国门诊高血压患者治疗现状登记研究[J].中华心血管病杂志,2010,38(3):230-238.
[5]Derosa G,Maffioli P.Nifedipine and telmisartan for the treatment of hypertension:the TALENT study[J].Expert Rev of Cardiovasc Ther,2011,9(12):1499-1503.
[6]Brown MJ,Mclnnes GT,Papst CC,et al.Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control(ACCELERATE):a randomised, parallel-group trial［J］. Lancet, 2011, 377(9762):312-320.
[7]Dahl?f B,Sever PS,Poulter NR,et al.Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomized controlled trial[J].Lancet,2005,366(9489):895-906.
[8]Julius S,Palatini P,Kieldsen SE,et al.Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension[J].Am J Cardiol,2012,109(5):685-692.
[9]de Champlain J,Karas M,Assouline L,et al.Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients[J].J Clin Hypertens,2007,9(3):168-178.
[10]Safar ME,Blacher J,Jankowski P.Arterial stiffness,pulse pressure,and cardiovascular disease-is it possible to break the vicious circle?[J].Atherosclerosis,2011,218(2):263-271.
[11]Ichihara A,Kaneshiro Y,Takemitsu T,et al.Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients[J].J Hum Hypertens,2006,20(10):787-794.
[12]Derosa G,Cicero AF,Carbone A,et al.Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies[J].J Am Soc Hypertens,2013,7(1),32-39.
[13]Koh KK,Han SH,Ahn JY,et al.Amlodipine improves endothelial function and metabolic parameters in patients with hypertension[J].Int J Cardiol,2009,133(1):23-31.
[14]Leask A.Potential therapeutic targets for cardiac fibrosis: TGFbeta,angiotensin,endothelin,CCN2,and PDGF,partners in fibroblast activation[J].Circ Res,2010,106(11):1675-1680.
[15]Rüster C,Wolf G.Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis[J].J Am Soc Nephrol,2011,22(7):1189-1199.

备注/Memo

备注/Memo:

收稿日期：2014-02-11.通讯作者:赵连友,主任医师,主要从事高血压发病的分子生物学机制及相关疾病防治研究 Email：zhaolyfmmu@ yahoo.com.cn 作者简介:玉晓露，硕士生 Email：yuxiaoluyuxiaolu@sina.com

常用功能

更新日期/Last Update: 2014-05-06